After seeing the third quarter results by Johnson and Johnson (NYSE: JNJ) released this morning we were hit by a wave of emotions. Before we get into which emotions let’s get the results out of the way as they flat out suck and not just for devices but drugs too. There is no need to go into detail for the simple fact is when it comes to diabetes and JNJ it’s over and the company is moving on. And at this point we really could care less if they are able to sell LifeScan or not. The harsh . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.